Investigational targeted drug induces responses in aggressive lymphomas
National Institutes of Health Mon, 02 Apr 2012 06:01 AM PDT
Preliminary results from clinical trials in a subtype of lymphoma show that for a number of patients whose disease was not cured by other treatments, the drug ibrutinib can provide significant anti-cancer responses with modest side effects. These results were presented as part of the opening plenary session at the American Association of Cancer Research (AACR) Annual Meeting 2012 on April 1 by ... |
Marple Newtown High students offer hope to those with cancer
Marple Newtown County Press Mon, 02 Apr 2012 05:54 AM PDT
Marple Newtown High School Interact Club recently held the American Cancer Society Daffodil Days to give hope to people facing cancer and save lives by supporting the program. The Daffodil Days program is a chance to fight back against cancer by raising funds and awareness to help beat the disease. While the Daffodil Days program involves offering daffodils every spring to donors in appreciation ... |
Dramatic rise of skin cancer in young adults
iTWire Mon, 02 Apr 2012 05:51 AM PDT
A 2012 U.S. study of melanomas showed a six times higher incidence in young adults than what was shown 40 years ago. The study points that women are in most danger because of their use of tanning beds and suntanning. |
Conn. teams set record for longest kickball game
San Francisco Chronicle Mon, 02 Apr 2012 05:47 AM PDT
(04-02) 05:05 PDT Naugatuck, Conn. (AP) -- A friendly game of kickball in Connecticut ended after 345 innings with a score of 164-117 and a Guinness world record. Two teams in Naugatuck raising money for cancer research... |
Have Your Say
BruDirect.com Mon, 02 Apr 2012 05:44 AM PDT
India's move to strip German drug maker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. |
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
Marketwire Mon, 02 Apr 2012 05:21 AM PDT
PORTLAND, OR--(Marketwire - Apr 2, 2012) - MolecularMD Corp. announces that it has closed a $6 Million Series B equity financing led by existing investor, Ballast Point Ventures, which is joined by new investor Nextech Invest, Ltd. MolecularMD is a fully integrated companion diagnostic partner to pharmaceutical companies developing targeted cancer therapies. Proceeds from the Series B investment ... |
| |
|